Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.

Tatar B., Köse Ş., Ergun N., Turken M., Onlen Y., Yılmaz Y., ...Daha Fazla

Revista da Associacao Medica Brasileira (1992), cilt.65, ss.1470-1475, 2019 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 65
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1590/1806-9282.65.12.1470
  • Dergi Adı: Revista da Associacao Medica Brasileira (1992)
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.1470-1475
  • Anahtar Kelimeler: Hepatitis C, End-Stage Renal Disease, Sustained Virologic Response, SUSTAINED VIRAL RESPONSE, VIRUS GENOTYPES, INFECTION, INTERFERON, METAANALYSIS, EFFICACY, OMBITASVIR/PARITAPREVIR/RITONAVIR, COMBINATION, IMPAIRMENT, MANAGEMENT
  • Recep Tayyip Erdoğan Üniversitesi Adresli: Hayır

Özet

OBJECTIVE:

The recent development of direct-acting antiviral agents (DAAs) has dramatically changed the treatment of chronic hepatitis C, and interferon-based regimes have become a poor treatment choice in clinical practice. Today DAAs offer shorter, well-tolerated, highly effective curative therapies. This study aimed to evaluate the effectiveness and safety of DAAs in patients with end-stage renal disease and HCV genotype 1 infection in real clinical practice.

METHODS:

Thirty-six patients who attended our clinic, were diagnosed with chronic hepatitis C (CHC), undergoing hemodialysis, and fulfilled the criteria of age >18 years, genotype 1 infection, with a detectable HCV RNA level were considered for the study. Patients with GT1a infection received OBV/PTV/r plus DSV plus RBV for 12 weeks; GT1b infected patients received this regimen without RBV for 12 weeks.

RESULTS:

The study was conducted on 33 patients. The mean age was 52.30 ±13.77 years, and 70 % of them were male. By the fourth week of treatment, HCV RNA levels decreased below 15 IU/ml in all patients. Sustained virologic response (SVR) 12 rate was 100%. Nine patients had side effects during treatment. Of the patients with side effects, 89.9% were in group 1a and 11.1% in group 1b.

CONCLUSION:

In this study, treatment with OBV/PTV/r and DSV with or without RBV resulted in high rates of sustained virologic response in HCV GT1-infected patients with end-stage renal disease (ESRD). SVR was achieved in all patients with few side effects.